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Exogenous Angiotensin II Does Not Facilitate
Norepinephrine Release in the Heart
Thomas W. Lameris, Sandra de Zeeuw, Dirk J. Duncker, Gooitzen Alberts, Frans Boomsma,
Pieter D. Verdouw, Anton H. van den Meiracker
Abstract—Studies on the effect of angiotensin II on norepinephrine release from sympathetic nerve terminals through
stimulation of presynaptic angiotensin II type 1 receptors are equivocal. Furthermore, evidence that angiotensin II
activates the cardiac sympathetic nervous system in vivo is scarce or indirect. In the intact porcine heart, we investigated
whether angiotensin II increases norepinephrine concentrations in the myocardial interstitial fluid (NEMIF) under basal
conditions and during sympathetic activation and whether it enhances exocytotic and nonexocytotic ischemia-induced
norepinephrine release. In 27 anesthetized pigs, NEMIF was measured in the left ventricular myocardium using the
microdialysis technique. Local infusion of angiotensin II into the left anterior descending coronary artery (LAD) at
consecutive rates of 0.05, 0.5, and 5 ng/kg per minute did not affect NEMIF, LAD flow, left ventricular dP/dtmax, and
arterial pressure despite large increments in coronary arterial and venous angiotensin II concentrations. In the presence
of neuronal reuptake inhibition and -adrenergic receptor blockade, left stellate ganglion stimulation increased NEMIF
from 2.70.3 to 7.31.2 before, and from 2.30.4 to 6.91.3 nmol/L during, infusion of 0.5 ng/kg per minute
angiotensin II. Sixty minutes of 70% LAD flow reduction caused a progressive increase in NEMIF from 0.90.1 to 166
nmol/L, which was not enhanced by concomitant infusion of 0.5 ng/kg per minute angiotensin II. In conclusion,
we did not observe any facilitation of cardiac norepinephrine release by angiotensin II under basal conditions and
during either physiological (ganglion stimulation) or pathophysiological (acute ischemia) sympathetic activation.
Hence, angiotensin II is not a local mediator of cardiac sympathetic activity in the in vivo porcine heart.
(Hypertension. 2002;40:491-497.)
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Activation of the sympathetic nervous system simulta-neously leads to activation of the renin-angiotensin
system via stimulation of -adrenergic receptors within the
kidney, resulting in an increased renin release. There is also
evidence, albeit conflicting, that the sympathetic nervous
system is activated by the renin-angiotensin system.1–13 This
activation supposedly occurs through stimulation of angio-
tensin II receptors within the central nervous system and/or
stimulation of presynaptic angiotensin II receptors located at
sympathetic nerve terminals. When investigating the sympa-
thetic nervous system and its interaction with the renin-an-
giotensin system, the heart is of particular interest. First of all,
the mammalian heart has a dense sympathetic innervation.
Second, all components of the renin-angiotensin system are
present in the heart, and most angiotensin II in the heart is
formed from locally synthesized angiotensin I.14 Third, in
conditions like hypertension, ischemia, and especially heart
failure, the renin-angiotensin system and sympathetic nervous
system are both activated, and this activation likely contrib-
utes to the deterioration of cardiac function.15–17
Evidence that angiotensin II activates the cardiac sympa-
thetic nervous system in vivo is scarce4 or indirect.7,18 In a
recent study, Teisman et al4 have shown with the use of the
microdialysis technique that “pharmacological” (106 mol/L)
concentrations of locally applied angiotensin II were associ-
ated with an increase in norepinephrine concentrations in the
myocardial interstitial fluid (NEMIF) of the in vivo rat heart. In
the present study, we determined whether “physiological”
(1010 mol/L) to “pathophysiological” (108 mol/L) concen-
trations of angiotensin II modulate NEMIF in the intact porcine
heart. The pig is especially suitable as a model for studying
the cardiac sympathetic nervous system because, unlike the
rat, the prevailing parasympathetic control of cardiac function
is very similar to that in man, which allows for a more reliable
extrapolation of the experimental results to the reality of
human patients.
To exclude a masking effect of neuronal norepinephrine
reuptake and negative feedback through presynaptic
-adrenergic receptor stimulation on modulation of NEMIF by
angiotensin II, we co-perfused some probes with the U1-
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inhibitor desipramine and the -adrenergic receptor-blocker
phentolamine without provoking systemic hemodynamic ef-
fects that also may modulate norepinephrine release.19–21
In those studies that demonstrated interaction between
angiotensin II and the sympathetic nervous system, most
evidence points toward direct facilitation mediated by pre-
synaptic angiotensin II type 1 (AT1) receptors resulting in
either a classic calcium-dependent augmentation of exocy-
totic norepinephrine release1–3 or in enhanced nonexocytotic
release via activation of the Na/H exchanger.22,23 There-
fore, we not only investigated the modulation of NEMIF by
angiotensin II under basal conditions but also during en-
hanced exocytotic norepinephrine release evoked by stimu-
lation of the left stellate ganglion. In addition, we monitored
norepinephrine release in MIF during reduction of left ante-
rior descending coronary artery (LAD) flow, resulting in both
exocytotic and nonexocytotic norepinephrine release,20 while
still allowing for intracoronary infusion of angiotensin II.
Methods
Animal Procedures
All experiments were performed in accordance with “Guiding
Principles for Research Involving Animals and Human Beings” as
approved by the Council of the American Physiological Society and
under the regulations of the Animal Care Committee of the Erasmus
University Rotterdam.
Crossbred LandraceYorkshire pigs of either sex (30 to 35 kg,
n27) were used. Treatment, surgical procedure, and positioning of
catheters and flow probes have been described previously.19,20 In
animals subjected to LAD flow reduction, a fluid-filled balloon
occluder (In Vivo Metric) was placed around the LAD distal to the
Doppler flow probe and attached to a bidirectional roller pump
(Ismatec). The voltage output from the Doppler equipment was
directed through a custom-built electrical circuit, which steered the
roller pump to maintain LAD flow at 30% of baseline values. In
animals subjected to sympathetic stimulation, the left stellate gan-
glion was dissected, and an electrode was inserted into the ganglion,
as described by Gootman et al,24 and connected to a nerve stimulator
(Grass S9; pulses of 12 V, 10 Hz, and 5 ms).
Microdialysis probes were implanted in the left ventricular (LV)
myocardium: 1 in the region perfused by the left circumflex coronary
artery (LCx) to determine NEMIF,LCx and 3 in the area perfused by the
LAD to determine NEMIF,LAD. To achieve local U1-inhibition, one of
the LAD probes was co-perfused with desipramine (100 mol/L,
Sigma),21 while another LAD probe was co-perfused with desipra-
mine and phentolamine (100 mol/L, Department of Pharmacy,
University Hospital Dijkzigt, Rotterdam) to block presynaptic
-adrenergic receptor-mediated inhibition of norepinephrine release.
The microdialysis technique, probe characteristics, handling of the
microdialysis and plasma samples for the measurement of norepi-
nephrine concentrations, and probe recovery have been described
previously.19,25 Plasma samples for determination of angiotensin II
concentrations (AngII) were rapidly drawn into chilled plastic
syringes containing an “inhibitor mix.”14
Experimental Protocol
After a 120-minute stabilization period, baseline measurements were
obtained over a 30-minute period. Probes were perfused with
Ringer’s solution (Baxter) at a flow of 2 L/min, and dialysate was
collected at 10-minute intervals, during which period blood was
collected from the aorta and the interventricular coronary vein.19,20 In
group I (n7), the effects of angiotensin II on basal sympathetic
norepinephrine release were investigated by infusing angiotensin II
(Department of Pharmacy) into the LAD at consecutive infusion
rates of 0.05, 0.5, and 5 ng/kg per minute for 20 minutes each. In
group II (n7), we assessed the effects of angiotensin II on enhanced
exocytotic norepinephrine release by stimulating the left stellate
ganglion before and during infusion of angiotensin II. To investigate
the effect of angiotensin II on nonexocytotic norepinephrine release,
the LAD flow was reduced by 70% for 60 minutes without (group
III, n6) and during simultaneous infusion of angiotensin II into the
LAD (group IV, n7). After 120 minutes of reperfusion, the LAD
perfusion area (area at risk) and infarct size were determined.20
Analytical Procedures
Norepinephrine concentrations in plasma and microdialysis samples
were determined by high performance liquid chromatography with
fluorometric detection.25 Plasma angiotensin II concentrations were
determined with high performance liquid chromatography after
Sep-Pak extraction and radioimmunoassay.14
Data Analysis and Statistics
Dialysate norepinephrine concentrations were corrected for probe
recovery to yield norepinephrine concentrations in MIF.19,20 Lower
limits of detection for norepinephrine in dialysate and plasma were
0.2 and 0.02 nmol/L, respectively.25 Baseline values were deter-
mined by averaging the 3 measurements over the 30-minute period
before intervention.19,20 Angiotensin II plasma concentrations in the
LAD were calculated from angiotensin II infusion rate, coronary
plasma flow (LADflow[1-hematocrit]), and arterial angiotensin II
concentrations. Results are expressed as meanSEM. For statistical
analysis two-way analysis of variance, one-way analysis of variance
for repeated measures with Dunnett’s multiple comparison test as
post hoc test, and Student t test were used as appropriate.
Results
Intracoronary Angiotensin II Infusion and Basal
Norepinephrine Concentrations (Group I)
During infusion of angiotensin II, angiotensin II concentra-
tions in the LAD and the coronary vein rose from 121 and
132 pmol/L at baseline up to 84851082 and 4150329
pmol/L during infusion of 5 ng/kg per minute, respectively
(Figure 1), while aortic angiotensin II concentrations in-
creased from 121 to 809 pmol/L. Despite these large
increments in angiotensin II concentrations, there were no
significant changes in global hemodynamics (Table 1), NEMIF,
or arterial and coronary venous norepinephrine concentra-
tions (Table 2 and Figure 2). However, LAD flow tended to
decrease, which necessitated increased myocardial O2 extrac-
tion, resulting in a decrease in coronary venous O2 saturation
(Table 1).
Figure 1. Intracoronary angiotensin II infusions and plasma an-
giotensin II concentrations in the interventricular coronary vein
(hatched bars) and left anterior descending coronary artery (sol-
id bars). Data are meanSEM, n7.
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Intracoronary Angiotensin II Infusion and
Norepinephrine Release During Sympathetic
Activation (Group II)
Stimulation of the left stellate ganglion caused marked
increases in blood pressure (19%), LAD flow (25%), and, in
particular, LV dP/dtmax (190%, Table 3 and Figure 3) and
caused a rise in NEMIF, particularly in the presence of U1- and
-adrenergic receptor blockade where NEMIF,LAD increased
from 2.70.4 to 7.31.2 nmol/L (Table 2 and Figure 3).
Concomitant intracoronary infusion of angiotensin II did not
affect hemodynamic responses to stimulation, nor did it
modify the stimulation-induced increase in NEMIF,LAD (from
2.30.3 to 6.91.3 nmol/L).
Intracoronary Angiotensin II Infusion and
Norepinephrine Release During Ischemia (Groups
III and IV)
Cardiovascular Function
The 70% LAD flow reduction resulted in 10% reductions of
mean arterial pressure and cardiac output, whereas LV
end-diastolic pressure slightly increased (Table 4). Following
reperfusion, mean arterial pressure and cardiac output re-
TABLE 1. Cardiovascular Function During Intracoronary Infusion of
Angiotensin II
Baseline
Angiotensin II, ng/kg per minute
0.05 0.5 5
Mean arterial pressure, mm Hg 832 805 833 853
Cardiac output, L/min 2.40.1 2.20.1 2.40.1 2.30.1
Heart rate, bpm 1345 1356 1356 1346
LV dP/dtmax, mm Hg/sec 155276 1472111 154787 155187
LV end diastolic pressure, mm Hg 121 111 111 121
LAD flow, mL/min 325 314 303 283
O2 Saturation, % 284 252 212* 211*
Data are meanSEM, n7.
*P0.05 versus baseline.
TABLE 2. Effect of Intracoronary Angiotensin II Infusion on Circulatory and Interstitial
Norepinephrine Concentrations
Arterial Plasma
(nmol/L)
Coronary Vein
(nmol/L)
MIF LAD
MIF LCx
(nmol/L)
Control
(nmol/L)
DMI
(nmol/L)
DMIPHA
(nmol/L)
Group 1 (n7)
Baseline 0.40.2 0.40.1 0.60.1 1.40.2†‡§ 2.30.4†‡§ 0.50.2
AngII 0.05 0.50.1 0.30.1 0.60.1 1.30.2†‡§ 2.10.2†‡§ 0.40.1
AngII 0.5 0.40.2 0.40.1 0.50.1 1.20.2†‡§ 2.10.4†‡§ 0.60.1
AngII 5 0.30.1 0.30.1 0.60.2 1.30.2†‡§ 2.20.5†‡§ 0.60.1
Group II (n7)
Baseline 0.10.0 0.20.1 0.50.1†‡ 1.70.4†‡§ 2.70.3†‡§ 0.60.1†‡
LSG stimulation 1.00.1* 1.70.7* 1.30.2* 3.10.6*†§ 7.31.2*†‡§ 1.40.5
AngII 0.5 0.10.0 0.30.1 0.70.1†‡ 1.60.2†‡§ 2.30.4†‡§ 0.50.2†
LSG stimAngII 0.5 1.30.1* 1.70.6* 0.90.1† 2.80.6†§ 6.91.3*†‡§ 1.20.6
Group III (n6)
Baseline 0.20.1 0.30.1 0.90.1†‡ 4.40.8†‡§ 5.00.7†‡§ 0.70.2†
Ischemia 0.20.0 1.40.6 16.25.7†‡* 12.34.0†‡* 14.35.4†‡* 0.50.1†§
Reperfusion 0.40.2 0.40.1 0.50.1* 1.40.2*†‡§ 2.30.4*†‡§ 0.50.1
Group IV (n7)
Baseline 0.10.1 0.20.3 0.90.3†‡ 5.20.6†‡§ 5.80.7†‡§ 0.60.1†
IschemiaAngII 0.5 0.20.1 0.90.2 10.93.8†‡* 11.23.5†‡* 14.13.5†‡* 0.60.1†§
Reperfusion 0.40.2 0.30.1 1.00.5 1.70.3*†‡ 2.20.4*†‡§ 0.70.2
AngII indicates intracoronary infusion of angiotensin II (ng/kg per minute); LSG, left stellate ganglion.
Intracoronary infusion of angiotensin II had no effect on circulatory or interstitial norepinephrine concentrations in any of the
experimental protocols. Data are meanSEM.
*P0.05 vs baseline; †P0.05 vs arterial plasma; ‡P0.05 vs coronary vein; §P0.05 vs MIF LAD (control); P0.05
desipramine vs desipraminephentolamine.
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mained depressed, whereas LV end-diastolic pressure re-
turned to baseline. In addition, heart rate increased and LV
dP/dtmax decreased. Angiotensin II infusion during ischemia
did not alter the hemodynamic response to ischemia and
reperfusion. Because LAD flow was kept at 30% of baseline
during ischemia, any effect of angiotensin II on LAD flow
was prevented.
Norepinephrine Concentrations
At baseline, NEMIF,LAD and NEMIF,LCx were similar and 3 times
the arterial norepinephrine concentration (P0.05; Table 2).
Under U1-blockade with desipramine, NEMIF,LAD increased
approximately 5-fold, irrespective of the presence of
-adrenoceptor blockade. NEMIF,LAD tripled during the first 20
minutes of ischemia and continued to rise up to 15-fold at 60
minutes of ischemia (Table 2, Figure 4). Under U1-inhibition,
the rate of rise of NEMIF,LAD was attenuated, so that, from 40
minutes of ischemia, NEMIF,LAD in the presence of desipramine
was similar to NEMIF,LAD without desipramine. On reperfusion,
NEMIF,LAD, NEMIF,LAD in the presence of desipramine, and
coronary venous norepinephrine concentrations declined rap-
idly, with the early rate of decline being most pronounced for
NEMIF,LAD without desipramine (Figure 4).
During ischemia, intracoronary infusion of angiotensin II
raised angiotensin II concentrations in the LAD from 91 to
2323231 pmol/L, whereas coronary venous concentrations
increased from 133 to 40846 pmol/L, indicating that
805% of angiotensin II was extracted over the coronary
bed. However, maximum NEMIF,LAD during the 60 minutes of
ischemia was not modified by concomitant angiotensin II
infusion (Table 2 and Figure 4). Within 120 minutes of
reperfusion, NEMIF,LAD and coronary venous norepinephrine
concentrations had returned to baseline and were similar for
groups III and IV. NEMIF,LCx and arterial norepinephrine
concentrations remained unchanged during the course of the
experiment in both groups.
Infarct Size
The 70% LAD flow reduction resulted in an ischemic area
(area at risk) that composed 324% of the LV mass in both
groups. Infarct size was 377% and 374% of the area at
risk in groups III and IV, respectively.
Discussion
This study provides no evidence for facilitation of cardiac
norepinephrine release by angiotensin II under various exper-
imental conditions in the intact porcine heart, because intra-
coronary infusion of angiotensin II did not modulate (1) basal
sympathetic tone, (2) exocytotic norepinephrine release dur-
ing sympathetic activation produced by left stellate ganglion
stimulation, or (3) exocytotic and nonexocytotic norepineph-
rine release during myocardial ischemia.
Intracoronary Angiotensin II Infusion and Basal
Cardiac Sympathetic Tone
Although the intracoronary angiotensin II infusions in our
experiments caused large increments in coronary venous
angiotensin II concentrations, no increments in interstitial or
coronary venous norepinephrine concentrations were ob-
served (Table 2). Inhibition of norepinephrine neuronal re-
uptake by co-perfusion of microdialysis probes with desipra-
mine and inhibition of the presynaptic 2-adrenergic receptor-
mediated negative feedback of norepinephrine release with
phentolamine did not unmask an angiotensin II-mediated
increase in NEMIF,LAD.
Although our findings agree with studies that also failed to
demonstrate an effect of angiotensin II on basal norepineph-
rine concentration and norepinephrine spillover,9–11 they are
at variance with other studies that have shown angiotensin II
to increase basal sympathetic tone.3,4 It could be argued that,
in anesthetized animals, facilitation of norepinephrine release
by angiotensin II is difficult to demonstrate because of low
basal norepinephrine concentrations compared those with
awake swine.26 However, Dendorfer and coworkers3 have
stated that facilitation of norepinephrine release by angioten-
sin II is in fact easier to demonstrate when background
sympathetic tone is low. An additional possible explanation
Figure 2. Effect of angiotensin II on basal cardiac sympathetic
tone. Data are shown for NEMIF,LAD (), NEMIF,LADdesipramine (),
NEMIF,LADdesipraminephentolamine (‘), NEMIF,LCx (), arterial
(solid bars), and coronary venous (hatched bars) norepinephrine
concentrations. AngII indicates intracoronary infusion of angio-
tensin II (0.5 ng/kg per minute). Data are meanSEM, n7.
TABLE 3. Intracoronary Angiotensin II Infusion and
Cardiovascular Function During Sympathetic Activation
Ang II Baseline LSG Stimulation
Mean arterial pressure, mm Hg  775 957*
 754 936*
Cardiac output, L/min  2.50.2 2.80.2*
 2.40.1 2.70.1*
Heart rate, bpm  1144 1154
 1115 1144
LV dP/dtmax, mm Hg/sec  1197103 3445340*
 1172102 3383233*
LV end diastolic pressure, mm Hg  112 92
 112 92
LAD flow, mL/min  274 364*
 274 354*
AngII indicates intracoronary infusion of angiotensin II (0.5 ng/kg per
minute).
Data are presented as meanSEM, n7.
*P0.05 vs baseline.
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for the discrepancy between our results and those of Dendorfer3
and Teisman4 is the difference between the dominant sympa-
thetic control of cardiac function in rats and dominant parasym-
pathetic control of cardiac function in pigs and also in humans,
which could imply that rat hearts are more sensitive to facilita-
tion of sympathetic activity by angiotensin II.
Angiotensin II may not only facilitate the neuronal
release of norepinephrine but may also inhibit its neuronal
reuptake.18,27 As neuronal reuptake is an important deter-
minant of NEMIF under baseline conditions as well as
during increased sympathetic tone,19,21 an increase in
NEMIF concentration through inhibiting neuronal reuptake
by angiotensin II would almost certainly have been de-
tected in this study.
We can also exclude that a putative facilitating effect of
angiotensin II on norepinephrine release was masked by a
hemodynamically mediated increase in norepinephrine
clearance. First, we used intracoronary angiotensin II
infusions to prevent significant systemic hemodynamic
effects. Second, the tendency of LAD flow to decrease
would have favored an increase in NEMIF by blunting
norepinephrine clearance. In fact, the angiotensin II-
associated increase in norepinephrine observed in some
studies might be explained by a decrease in clearance
caused by angiotensin II-induced vasoconstriction.4
Intracoronary Angiotensin II Infusion and
Norepinephrine Release During
Sympathetic Activation
In the present study, sympathetic stimulation was induced by
electrical stimulation of the left stellate ganglion, resulting in
marked increases in LV dP/dtmax, blood pressure, and LAD
flow. These hemodynamic effects were not enhanced by an
intracoronary infusion of angiotensin II (Table 3 and Figure
3). Similarly, ganglion stimulation increased NEMIF up to
5-fold. In the presence of U1- and -adrenoceptor blockade,
the absolute increase in NEMIF was the most substantial,
suggesting an important negative feedback mechanism
through presynaptic -adrenergic receptors, most likely of the
2-subtype. Again, infusion of angiotensin II did not augment
this increase, irrespective of the presence of U1- and
-adrenergic receptor blockade (Table 2 and Figure 3). These
results are in agreement with other studies that also failed to
demonstrate enhanced norepinephrine release by angiotensin
II during sympathetic activation in humans with and without
chronic heart failure,10–12 and in particular with Rundqvist et
al,8 who demonstrated that intracoronary administration of
the angiotensin-converting enzyme (ACE) inhibitor enalapri-
lat failed to attenuate the increase in cardiac norepinephrine
spillover following sympathetic activation. In contrast, other
studies using electrical stimulation in vitro,1,2,5 as well as
studies in humans,6,7 did demonstrate angiotensin II-induced
Figure 3. Effect of angiotensin II on LV dP/dtmax (left
panel) and NEMIF,LADdesipraminephentolamine
(right panel) during left stellate ganglion (LSG) stimu-
lation. Data are meanSEM, n7. ***P0.001 ver-
sus prestimulation values.
TABLE 4. Intracoronary Infusion of Angiotensin II and Cardiovascular Function
During Ischemia
AngII Baseline
Ischemia
(60 min)
Reperfusion
(120 min)
Mean arterial pressure, mm Hg  952 891 853*
 933 866 794*
Cardiac output, L/min  2.70.2 2.40.2* 2.30.1*
 2.70.1 2.30.1* 2.00.2*
Heart rate, bpm  1214 1276 1366*
 1176 1246 13810*
LV dP/dtmax, mm Hg/sec  1994141 183385 1615104*
 1668111 1554115 1458181
LV end diastolic pressure, mm Hg  122 142 121
 62 92* 82
LAD Flow, mL/min  274 81* 356
 353 101* 445*
AngII indicates intracoronary infusion of angiotensin II (0.5 ng/kg per minute).
Data are meanSEM (AngII, n6; AngII, n7).
*P0.05 vs baseline.
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augmentation of sympathetic activation. Three of these stud-
ies were on the heart.2,5,7 Of the latter, only the study by Saino
and colleagues7 investigated augmentation of sympathoneural
activation by angiotensin II in the intact (human) heart.
However, because they did not measure norepinephrine
spillover or norepinephrine concentrations directly but esti-
mated differences in sympathetic activity by comparing
responses of coronary blood flow and coronary vascular
resistance to the diving and cold-pressure tests, with and
without simultaneous intracoronary angiotensin II infusion, it
cannot be excluded that vasomotor mechanisms other than
-adrenoceptor–mediated vasoconstriction, as a result of
facilitated norepinephrine release, are responsible for the
observed hemodynamic responses.
Intracoronary Angiotensin II Infusion and
Norepinephrine Release During Ischemia
Because angiotensin II has been reported to enhance either
nonexocytotic norepinephrine release via activation of the
Na/H exchanger22,23 or exocytotic release via classic
calcium-dependent facilitation,1,3 we monitored norepineph-
rine release in MIF during myocardial ischemia produced by
LAD flow reduction, which leads to both exocytotic and
nonexocytotic norepinephrine release while still permitting
intracoronary infusion of angiotensin II during ischemia. The
NEMIF increase during 70% flow reduction (15-fold) was
much less than previously described during total occlusion
(500-fold),20 not only because ischemia was less severe but
also because washout of released norepinephrine is partially
preserved during 70% flow reduction. We kept LAD flow
constant at 30% of baseline, thereby preventing any potential
effects of angiotensin II on flow-induced changes in norepi-
nephrine clearance (Table 4). During flow reduction, con-
comitant infusion of angiotensin II neither augmented the
ischemia-induced increase in NEMIF nor altered its time course
(Table 2, Figure 4). Our findings are at variance with the
attenuation of ischemia-induced norepinephrine re-
lease,23,28,29 as well as the decrease in sympathetic activity in
heart failure18,30,31 by ACE-inhibitors or AT1-receptor block-
ers, which had been reported earlier. Several factors may
contribute to these apparent conflicting results. (1) Diffusion
limitations for angiotensin II from the bloodstream to the
perivascular or myocardial sympathetic nerve terminals could
have prevented the infused angiotensin II from reaching the
interstitial space and occupying AT1 receptors.8 However,
this is unlikely, as we have previously shown that the cardiac
tissue concentration of radiolabeled 125I-angiotensin II during
125I-angiotensin II infusion was 75% of its arterial concentra-
tion and that most of this angiotensin II is bound to AT1
receptors.14 (2) Although inhibition of the renin-angiotensin
system may exert a direct effect on norepinephrine release in
chronic heart failure,18,30,31 the decrease in plasma norepi-
nephrine concentrations during treatment of heart failure with
ACE-inhibitors or AT1-receptor blockers might also be due to
an improvement of cardiac function. (3) The decrease in
sympathetic tone with these agents18,23,28–31 might not be
mediated through peripheral presynaptic AT1 receptors, but
by other mechanisms. For instance, ACE-inhibitors do not
only inhibit angiotensin I to angiotensin II conversion, but
also limit bradykinin degradation and stimulate prostaglandin
formation. Both bradykinin and prostaglandins have been
shown to inhibit norepinephrine release.28,32 In addition, the
interaction between the renin-angiotensin system and the
sympathetic nervous system might be mediated through
central AT1 receptors in the brain.33–35 (4) Facilitation of
norepinephrine release by presynaptic AT1-receptor activa-
tion might be counteracted by presynaptic AT1 receptors,
which can inhibit norepinephrine release and are down-
regulated in cardiomyocytes of patients with chronic heart
failure.22,23,36
Perspectives
In this study in pigs, in which, contrary to rats, cardiac
function is predominantly parasympathetically controlled, we
did not find evidence for facilitation of cardiac norepineph-
rine release by exogenous angiotensin II under baseline
conditions and during sympathetic activation by either stel-
late ganglion stimulation or acute ischemia, indicating that
angiotensin II is not a local mediator of cardiac sympathetic
nerve activity. The design of the study does not exclude
facilitation of cardiac norepinephrine release by angiotensin
II through stimulation of presynaptic AT1 receptors at sym-
pathetic nerve terminals under pathological conditions such
as hypertension and heart failure. In a previous study, we
observed an upregulation of AT1 receptors in the remodeled
hypertrophied myocardium, as well as increased circulatory
concentrations of angiotensin II during exercise, 1 to 3 weeks
after infarction.26 If angiotensin II facilitates norepinephrine
release via stimulation of presynaptic angiotensin II recep-
tors, the latter model may be particularly suited to address this
Figure 4. Effect of angiotensin II on the time course
of changes in norepinephrine concentrations during
70% LAD flow reduction (70% FR) and reperfusion.
Data are shown for NEMIF,LAD (), NEMIF,LAD
desipramine (), NEMIF,LADdesipraminephentol-
amine (‘), NEMIF,LCx (), arterial (solid bars), and cor-
onary venous (hatched bars) norepinephrine concen-
trations. Data are meanSEM, n6 (left panel) and
n7 (right panel).
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question, and research to explore this issue is under way.
Furthermore, because of intrinsic activation of the renin-an-
giotensin system, this model is also well suited to explore
whether local inhibition of the renin-angiotensin system with
AT1-receptor antagonists is associated with a decrease in
myocardial norepinephrine release.
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